CITED2 and pancreatic adenocarcinoma: We found that PAAD patients with overexpression of JMJD6, NDST1, ENO3, ANKZF1, and CITED2 had a relatively favorable prognosis, while patients with high levels of LDHA, TES and SIAH2 had poor survival outcomes (Figure 5B).